Scalp cooling for reducing alopecia in gynecology oncology patients treated with dose-dense chemotherapy: A pilot project.
Alopecia
Chemotherapy
Gynecology oncology
Scalp cooling
Journal
Gynecologic oncology reports
ISSN: 2352-5789
Titre abrégé: Gynecol Oncol Rep
Pays: Netherlands
ID NLM: 101652231
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
received:
08
05
2021
revised:
21
07
2021
accepted:
22
07
2021
entrez:
17
8
2021
pubmed:
18
8
2021
medline:
18
8
2021
Statut:
epublish
Résumé
Determine the efficacy of scalp cooling for the prevention of chemotherapy-induced alopecia in gynecology oncology patients. This prospective pilot study included patients diagnosed with a gynecological malignancy that received DigniCap™ scalp cooling. Patients were divided into two groups based on chemotherapy regimen: Carboplatin with area under the curve (AUC) 5-6 every three weeks and (1) conventional Paclitaxel 175 mg/m Hair preservation occurred with use of a scalp cooling device for patients receiving weekly Paclitaxel (n = 20), but not conventional every three weeks Paclitaxel (n = 8). Ten of 15 patients (66.7%) in the dose-dense group lost less than 50% of their hair based on self-assessment and 14 of 16 (87.5%) based on dermatologist assessment. No patient in this group acquired a cranial prosthesis (wig). There was no difference between groups in terms of quality of life (QoL) and BIS scores. Scalp cooling may allow for hair preservation in gynecology oncology patients receiving Carboplatin AUC 5-6 and weekly Paclitaxel 80 mg/m
Identifiants
pubmed: 34401437
doi: 10.1016/j.gore.2021.100842
pii: S2352-5789(21)00146-6
pmc: PMC8355950
doi:
Types de publication
Case Reports
Langues
eng
Pagination
100842Informations de copyright
© 2021 The Author(s).
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
J Eur Acad Dermatol Venereol. 2018 May;32(5):720-734
pubmed: 28976026
Scand J Clin Lab Invest. 1985 Oct;45(6):505-8
pubmed: 4070952
Curr Oncol. 2016 Dec;23(6):e576-e582
pubmed: 28050147
Eur J Cancer. 2001 Jan;37(2):189-97
pubmed: 11166145
Acta Obstet Gynecol Scand. 2021 Mar;100(3):453-458
pubmed: 33048344
Breast Cancer Res Treat. 2021 Jan;185(2):453-458
pubmed: 33125621
J Natl Compr Canc Netw. 2021 Feb 02;19(2):191-226
pubmed: 33545690
Gynecol Oncol. 2017 Oct;147(1):30-35
pubmed: 28735629
JAMA. 2017 Feb 14;317(6):596-605
pubmed: 28196254
Psychooncology. 2010 Jul;19(7):701-9
pubmed: 19637250
Eur J Cancer. 1990;26(10):1038-42
pubmed: 2148877
Br J Nurs. 2011 May 27-Jun 9;20(10):S4-11
pubmed: 21647004
Ann Oncol. 2005 Mar;16(3):352-8
pubmed: 15642703
Cancer Nurs. 2020 Sep 25;:
pubmed: 33003120
Psychooncology. 2004 Oct;13(10):729-39
pubmed: 15386642
JAMA. 2017 Feb 14;317(6):606-614
pubmed: 28196257
Breast Cancer Res Treat. 2019 Jan;173(1):135-143
pubmed: 30255454
Cancer Pract. 2001 Nov-Dec;9(6):283-9
pubmed: 11879330
Patient Educ Couns. 2004 Mar;52(3):333-9
pubmed: 14998604
Int J Cancer. 2015 Mar 1;136(5):E442-54
pubmed: 25081068
In Vitro Cell Dev Biol Anim. 2008 Mar-Apr;44(3-4):81-6
pubmed: 18193326
J Natl Cancer Inst. 1993 Mar 3;85(5):365-76
pubmed: 8433390
Support Care Cancer. 2021 Apr 13;:
pubmed: 33847828
Cancer Nurs. 2005 Sep-Oct;28(5):382-9
pubmed: 16192830
Clin Breast Cancer. 2018 Feb;18(1):19-28
pubmed: 28939291
Oncol Nurs Forum. 2002 Jan-Feb;29(1):113-9
pubmed: 11817485
Breast Cancer Res Treat. 2017 Jun;163(2):199-205
pubmed: 28275922
Perspect Psychiatr Care. 2012 Apr;48(2):116-21
pubmed: 22458725
Breast Cancer Res Treat. 2019 Jun;175(2):267-276
pubmed: 30806923
Cancer. 2002 Jul 1;95(1):155-63
pubmed: 12115329